Clinical Study Of Concurrent Radiochemotherapy Combined With Hyperthermia In The Treatment Of Locally Advanced Non-Small Cell Lung Cancer

Objective: Lung cancer is a common malignant tumor in clinical practice.In China,the incidence and mortality of lung cancer rank first in malignant tumors.Non-small cell lung cancer(NSCLC)accounts for 80% of all lung cancer.More than one-third of NSCLC patients have a stage IIIA or IIIB for the first visit,some of which can be treated surgically,however,the vast majority lose the opportunity for optimal surgical treatment.For many years,the treatment of locally advanced NSCLC was mainly based on radiotherapy(RT),but its 5-year overall survival rate was only about 5%.Therefore,in order to improve the prognosis of patients with locally advanced NSCLC,further treatments are needed.In recent years,hyperthermia,as an emerging green treatment for cancer treatment,has received more attention from everyone.It can not only directly kill tumor cells,but also can be used as radiosensitizers and chemical sensitizers to further improve treatment.Efficacy.This article aims to investigate the clinical efficacy and side effects of hyperthermia combined with radiotherapy and chemotherapy in the treatment of locally advanced NSCLC.Methods: In this study,120 patients with local advanced NSCLC who met the conditions in the First Affiliated Hospital of Zhengzhou University were selected and divided into the control group and the experimental group according to the treatment.The experimental group used chemotherapy,radiotherapy combined with hyperthermia treatment mode.Among them,radiotherapy used volumetric modulated arc therapy(VMAT),the dose was 1.8~2.0Gy/F,5F/week,GTV60~66Gy/30~33F Cervical lymph node metastasis plus neck radiotherapy DT50~56Gy/ 25~28F,during the radiotherapy,platinum-based chemotherapy,paclitaxel + cisplatin or carboplatin(135-175 mg / m2,d1;Platinum 75 mg/m2,d1 or carboplatin AUC=5-6,d1;q3w for 2 cycles)or docetaxel + cisplatin or carboplatin(docetaxel 75 mg/m2,d1,q3w)Or gemcitabine + cisplatin / carboplatin(gemcitabine 1000 mg / m2,d1,d8,q3w)or pemetrexed + cisplatin / carboplatin(pemetrexed 500 mg / m2,d1,q3w);combined hyperthermia,30 minutes after radiotherapy,the temperature of the hyperthermia was controlled at 41℃~42℃,about 60 min each time,twice a week.The control group used the treatment mode of chemotherapy combined with radiotherapy,and its usage was the same as above.The concurrent chemoradiotherapy regimen was the same as the observation group.After two years of follow-up,the short-term efficacy,toxicity,and 1-year and 2-year survival rates and progression-free survival were compared between the two groups.Results: 1.The experimental group had complete response(CR)in 11 cases,partial response(PR)in 41 cases,stable disease(SD)in 7 cases,progressive disease(PD)in 1 case,and efficiency(response)The rate,RR)was 88.67%;the control group was 9 cases,the PR was 34 cases,the SD was 14 cases,the PD was 3 cases,and the RR was 71.67%.The difference between the two groups was statistically significant(P<0.05).2.The toxic and side effects related to treatment in the two groups were mainly chemoradiotherapy,including leukopenia,thrombocytopenia,anemia,nausea and vomiting,radiation esophagitis,radiation pneumonitis,etc.There was no significant difference in the incidence of toxic and side effects between the two groups.(P>0.05).3.The 1-year and 2-year overall survival rates were compared,81.67% vs 65.00%(P=0.039),51.67% vs 33.33%(P=0.042);1-year and 2-year progression-free survival rates were 63.33% vs 45.00%(P=0.044),38.33% vs 21.67%(P=0.046),the difference was statistically significant(P<0.05).Conclusions: Compared with concurrent chemoradiotherapy,hyperthermia combined with concurrent chemoradiotherapy improves the short-term efficacy of advanced local NSCLC without increasing toxic and side effects,and improves survival rate,which is safe and effective.